Current seasonal influenza vaccines are not likely to provide protection against novel influenza A (H1N1) virus even the 
signs and symptoms of novel influenza A (H1N1) virus infection are similar to those of seasonal influenza. Therefore, a licensed specific influenza A (H1N1) virus vaccine is being manufactured and expected to be ready in US by mid-October 2009. Since the vaccines might not be enough to supply the demand, herein the CDC recommendation to use these vaccines.
This recommendations was prepared by CDC’s Advisory Committee on Immunization Practices (ACIP). Accordingly, the principle in this recommendations is to vaccinate as many persons as quickly as possible. You will find sections describe you with the background on the use of Influenza A (H1N1) vaccine (clinical features, age group of persons hospitalized with laboratory-confirmed influenza in US, Epidemiology and Transmission of Influenza A (H1N1)).
Also, you will be taken into informations about Vaccination Against Novel Influenza A (H1N1) Virus Infection (Licensure of vaccines, vaccine formulations/ingredient that contain no adjuvant including FDA recommendation), and Recommended Use of Influenza A (H1N1) 2009 Monovalent Vaccine (Initial Target Groups, Subset of Target Groups During Limited Vaccine Availability, Expanding Vaccination Efforts Beyond Initial Target Groups).
Please complete your read about The CDC Recommendations Use of Influenza A (H1N1) 2009 Monovalent Vaccine here or you can download this H1N1 Vaccine Recommendation in pdf filetype. Any updated information will be published by CDC at http://www.cdc.gov/flu.
